Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

Yukihiro Toi, Shunichi Sugawara, Jun Sugisaka, +14

JAMA Oncology

Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab

Yukihiro Toi, Shunichi Sugawara, Yosuke Kawashima, +13

The Oncologist

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Abdul Rafeh Naqash, Biagio Ricciuti, Dwight H. Owen, +15

Cancer Immunology Immunotherapy

Cancer EpidemiologyPooled Exploratory AnalysisMedicineCancer ManagementImmunology +6

CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion

Yasushi Sasaki, Ryota Koyama, Reo Maruyama, +7

Cancer Biology & Therapy

Cancer Cell MigrationFocal Adhesion KinaseCell RegulationCell SignalingMedicine +13

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer

Mari Aso, Yukihiro Toi, Jun Sugisaka, +15

The Oncologist

Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

Jun Sugisaka, Yukihiro Toi, Masataka Taguri, +15

JMA Journal

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer

Kana Ono, Hirotaka Ono, Yukihiro Toi, +19

Cancer Medicine

Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer

Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, +17

Journal for ImmunoTherapy of Cancer

Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers

Tomoiki Aiba, Chieko Hattori, Jun Sugisaka, +14

PLoS ONE

Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.

Yukihiro Toi, Yuichiro Kimura, Yutaka Domeki, +14

PubMed Central